ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALK+ Summit 2022 in Denver, CO was largest Summit yet!!
Date: July 29th-31st Attendees: in-person: 250 Virtual: 850 The ALK Positive annual summit was once again a huge success! This year the event was held both in Denver, Colorado and virtually (online). We had 250 individual registrations in-person and 850 virtual attendees. Our ALK Summit in Denver was a great opportunity to…
-
Dr. Kenneth Culver named Director of Research & Clinical Affairs for ALK Positive Inc.
We are excited to welcome Dr. Kenneth Culver as our first Director of Research & Clinical Affairs! Dr. Culver graduated from the University of Iowa College of Medicine in 1981. He completed his internship and residency in Pediatrics and a fellowship in Pediatric immunology at the University of California, San Francisco. At UCSF, he developed…
-
Pre-Clinical Research Sets the Stage for Clinical Trials
Clinical trials are studies that are done in humans to test a new treatment. Long before a clinical trial, a host of “pre-clinical” studies must test the feasibility, safety, and effectiveness of a new treatment. Preliminary work involves chemistry to develop a compound that can be manufactured and has the potential to inhibit cancer growth.…
-
Phase 1 Clinical Trial NCT05346494 by Imugene Limited
VAXINIA study of CF33-hNIS, an oncolytic virus, as monotherapy or in combination with Pembrolizumab, in adults with metastatic or advanced solid tumors (MAST), including NSCLC: Check ClinicalTrials.gov Imugene’s CF33, or Vaxinia, is a modified DNA virus of the Poxviridae family developed by Professor Yuman Fong at the City of Hope Comprehensive Cancer Center in Los…
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem that we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known mechanisms of resistance so far. One is for the cancer cells to activate an alternative bypass pathway such as EGFR, cMET, KRAS, or AXL…
-
PATIENT SPOTLIGHT: Ruby Blow, Atlanta, GA, USA
Please enjoy our interview with the wonderful and courageous Ruby Blow! 1) Share with us a little bit about yourself, including your personal life, your professional background, and your journey with lung cancer so far. I am a sister, an aunt, and a professional counselor. I have my own practice. I stopped seeing therapy clients,…
-
Butternut Squash, Spinach, and Spicy Sausage Soup with Orzo Recipe
This comforting soup makes a delicious and savory soup that’s perfect for those cold busy nights in the Fall and Winter when butternut squash is also in season. *feel free to substitute sweet pork sausage in this recipe if spicy isn’t your thing! One pot – 30 minutes start to finish!
-
A New Clinical Trial in Italy: Does Supervised Exercise Improve Outcomes in Oncogene Addicted Lung Cancer?
For those diagnosed with advanced lung cancer, there is often the question of how lifestyle changes can improve the prognosis. A unique study in Italy called EXcellenT will measure how supervised exercise affects outcomes. Those who have a positive biomarker, like ALK, can participate if they are on their first or second tyrosine kinase inhibitor…
-
FDA approves crizotinib for ALK-positive inflammatory myogibroblastic tumor
On July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). The safety and efficacy of crizotinib were evaluated in two multicenter, single-arm, open-label trials that included 14…
-
The Latest & Greatest from ALK Positive Inc.
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients, and/or caregivers. The Board, Committees, and our CEO, are working together to improve the life expectancy and…
-
ALKOVE Clinical Trial: a 4th Generation TKI from Nuvalent
The Phase 1/2 trial of Nuvalent, Inc.’s NVL-655, the fourth generation ALK TKI, has begun at Sarah Cannon Research Institute in Nashville, soon to be followed by additional locations. Below is a brief summary of the trial, with connections to relevant websites for more information. For patients currently on Lorlatinib, NVL-655 provides a hope-filled option…
-
ALK Positive Inc. at ASCO (June 3-7, 2022)
“Going to ASCO was a great opportunity to network and represent the organization, help move ALK to the top, and let people know who we are. I feel it was a productive conference, and we look forward to continuing better relationships with everyone. As a patient-led organization, it is important for us that they see…